Wyeth

Columbia University

Northwestern University

Rutgers, the State University of New Jersey

Biohaven Pharmaceutical Holding Company Limited

Biohaven Therapeutics Ltd.

Yale University

Bearsden Bio, Inc.

Pfizer Ireland Pharmaceuticals

Kleo Pharmaceuticals, Inc.

Bearsden Bearsden Bio, Inc.

Jeffrey Claude Pelletier

Allen B Reitz

Jay Edward Wrobel

Garry Robert Smith

Ottavio Arancio

Daniel Martin Watterson

Saktimayee Mitra Roy

Mark E McDonnell

Benjamin E Blass

Suzie Chen

Matthew D Vera

Venkata N Velvadapu

John Francis Rogers, Jr

Haiyan Bian

Charles William Mann

Matthew Douglas Vera

Daniel Michael Green

Diane Barbara Hauze

Joseph Theodore Lundquist, Iv

Mark Anthony Ashwell

David Spiegel

Gene Michael Dubowchik

Robert J Steffan

William Ronald Solvibile

Yansong Gu

Kenneth L Kees

Matthew Welsch

H Marie Loughran

Edward Martin Matelan

Charles M Conway

Lloyd Michael Garrick

John Francis Mehlmann

Mark A Collins

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

Riluzole prodrugs and their use

Prodrugs of riluzole and their method of use

Disclosed are prodrugs of CGRP antagonists, methods of treating CGRP related disorders, e.g., migraine, by administering to a patient in need thereof the prodrugs, pharmaceutical compositions comprising prodrugs and kits including the pharmaceutical compositions and instructions for use.

Prodrugs of CGRP antagonists

The invention provides for novel MAP kinase inhibitors and compositions comprising the same. In some embodiments, the MAP kinase inhibitors are p38&#x3b1; MAP kinase inhibitors. The invention further provides for methods for treatment of diseases comprising administration of MAP kinase inhibitors or compositions comprising MAP kinase inhibitors. In some embodiments, the disease is Alzheimer's Disease, ALS, Huntington's Disease or Parkinson's Disease.

MAP kinase modulators and uses thereof

The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic and other cancers where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds bind to the urokinase-type plasminogen activator receptor (uPAR) on the surface of a cancer cell, including a metastatic cancer cell, and consequently recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) against a large number and variety of cancers, thus providing cancer cell death and an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.

Antibody-recruiting molecules for the treatment of cancer

Map kinase modulators and uses thereof

Compounds of Formula I, useful as Gonadotropin Releasing Hormone ('GnRH') (also known as Leutinizing Hormone Releasing Hormone) receptor antagonists, are disclosed. 

Gonadotropin releasing hormone receptor antagonists

The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.

7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor

Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor

4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor

Growing community of inventors

Lafayette Hill, PA, United States of America

Jeffrey Claude Pelletier